Investor Relations

Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Toolkit

Latest Press Releases

View our most latest Press Releases.

Latest Quarterly Results

View our most recent Quarterly Earnings.

View Our Filings

Our most up-to-date summary of our financial performance.

Kymera Cares

Our team’s shared commitment to improving people’s lives extends beyond our work to develop groundbreaking new medicines.

Stay Connected

Investor & Media Contact
Justine Koenigsberg
Vice President, Investor Relations